- Merck plans to acquire Acceleron Pharma for about $11.5 billion to expand its rare disease drug portfolio.
- Sanofi will acquire New York City-based drugmaker Kadmon for $1.9 billion.
- Pfizer entered into a definitive agreement to buy Canadian cancer drugmaker Trillium Therapeutics for $2.26 billion.
- Bayer has acquired San Diego-based biotech Vividion Therapeutics for $1.5 billion up front, with $500 million in potential success-based milestone payments.
- Sanofi will acquire clinical-stage mRNA therapeutics company Translate Bio for $3.2 billion.
- PerkinElmer is buying antibody and reagents maker BioLegend in a $5.25 billion deal.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
